We previously showed that 3"-deoxy-cyclic ADP-carbocyclic-ribose (3"-deoxy-cADPcR, 2) is a stable and highly potent analogue of cyclic ADP-ribose (cADPR, 1), a Ca 2+ -mobilizing second messenger. From these results, we newly designed another 3"-modified analogues of cADPcR and identified the N1-"xylo"-type carbocyclic analogue, i.e., cADPcX (4), as one of the most potent cADPR-related compounds reported so far.
INTRODUCTION
Much attention has been focused on cyclic ADP-ribose ( cADPR, 1, FIGURE 1) , a naturally occurring metabolite of NAD + , 2 due to the biological interest. 3 cADPR has been shown to mobilize intracellular Ca 2+ in various cells, and is now recognized as a general mediator involved in Ca 2+ signaling. 3 Under neutral conditions, cADPR is in a zwitterionic form with a positive charge around the N(1)-C(6)-N 6 moiety (pK a = 8.3), making the molecule unstable. The charged adenine moiety attached to the anomeric carbon of the N1-ribose can be an efficient leaving group. Accordingly, cADPR is readily hydrolyzed at the unstable N-1-ribosyl linkage of its adenine moiety to produce ADP-ribose (ADPR), even in neutral aqueous solution. 4 Under physiological conditions, cADPR is also hydrolyzed at the N-1-ribosyl linkage by cADPR hydrolase to give the inactive ADPR. 4 cADPR analogues can be used in proving the mechanism of cADPR-mediated Ca 2+ signaling pathways and are also expected to be lead structures for the development of drugs, since cADPR has been shown to play important physiological roles. 3 Therefore, the synthesis of cADPR analogues has been extensively investigated by enzymatic and chemo-enzymatic methods using ADP-ribosyl cyclase-catalyzed cyclization. However, the analogues obtained by these methods are limited due to the substrate-specificity of the ADP-ribosyl cyclase. 3 On the other hand, in the chemical synthesis of cADPR and its analogues, construction of the large 18-membered ring structure is the key step, and we recently developed an efficient method for forming the 18-membered ring employing phenylthiophosphate-type substrates. 5 When these substrates were activated by AgNO 3 or I 2 in the presence of molecular sieves in pyridine, the corresponding 18-membered ring products were obtained in high yields. 5b,c Using this method, we successfully synthesized cyclic ADP-carbocyclic-ribose (cADPcR, 2), 5c designed as a stable mimic of cADPR, in which the oxygen atom in the N-1-ribose ring of cADPR is replaced by a methylene group. Biological evaluation of cADPcR showed that it actually act as biologicically and chemically stable equivalent of cADPR. 5c Based on these results, we have investigated further synthetic and biological studies on N1-carbocyclic derivatives of cADPR. 6 In the course of these studies, we describe here the synthesis and biological evaluation of newly designed analogues of cADPcR, which are cyclic ADP-carbocyclic-xylose (cADPcX, 4) and the corresponding 3"-O-methyl derivative (3"-OMe-cADPcX, 5).
RESULTS AND DISCUSSION
Design and Synthetic Plan. We previously showed 1) that cADPcR (2) is actually resistant to both enzymatic and chemical hydrolysis, since it has a chemically and biologically stable N-alkyl linkage instead of the unstable N1-glycosidic linkage of cADPR, 5b 2) that cADPcR has a conformation similar to that of cADPR, 6c and 3) that cADPcR, like cADPR, effectively mobilizes intracellular Ca 2+ in sea urchin eggs and neuronal cells. 5c,6b,c Furthermore, we have investigated SRA of the N1-ribose moiety of cADPcR and clarified that modification at the N1-ribose moiety changes the biological potency. 6b,c Throughout these studies, we also found that although deletion of the 2"-hydroxy group resulted in a marked reduction of potency, deletion of the adjacent 3"-hydroxy group (3"-deoxy-cADPcR, 3) greatly potentiated the Ca 2+ -mobilizing ability in sea urchin eggs. 6c These results suggest that modification at the 3"-position may improve the biological potency of cADPR and its analogues. Thus, we newly designed another 3"-modified analogues of cADPcR, which were the N1-"xylo"-type carbocyclic analogue, i.e., cADPcX (4) and the corresponding O-methyl analogue 5.
As described above, we have developed an efficient total synthetic method for cADPR analogues, 5 which we 6 and other groups 7 have effectively used in the synthesis of a variety of cADPR analogues. Thus, we planned to synthesize the target compounds based on the previous total synthetic method.
The synthetic plan is shown in SCHEME 1 as a retrosynthetic analysis. The chiral carbocyclic-xylosyl amines III, composing the N1-substituted moiety in the targets 4 and 5, could be prepared from commercially available (1R)-(-)-2-azabicyclo[2.2.1]hept-5-en-3-one (8) . From these carbocyclic amines III and the known imidazole nucleoside derivative 6, 5b the 5'-phenylthiophosphate-type substrates II for the key intramolecular condensation could be prepared. Treatment of II with AgNO 3 /MS 3A as a promoter 5a,b was expected to form the cyclized products I, and subsequent acidic treatment for deprotection would furnish the desired cADPcR analogues 4 and 5.
Synthesis. The carbocyclic-xylosyl amine units 14a and 14b were synthesized from the optically active bicyclic lactam 8, as summarized in Scheme 2. After protection of the primary hydroxyl with a triisopropysilyl (TIPS) group of cabocylicilc-ribose derivative 9, prepared from 8 according to the previously reported method, 6c treatment of the resulting 10 under Mitsunobu reaction conditions with ClCH 2 CO 2 H/DIAD/Ph 3 P gave the corresponding 3-position-inverted product 11, and subsequent removal the 3-O-chloroacetly group with NaOMe/MeOH to afford the carbocyclic-xylose derivative 12. The 3-hydroxy of 12 was protected with a MOM group under usual conditions or methylated with MeOTf and 2,6-di-tert-butyl-4-methylpyridine (DTBMP), followed by removal of the TIPS group, to give the desired 3-O-MOM-ptotected unit 14a or the 3-O-methyl unit 14b, respectively.
The target 3"-modified cADPcR analogues 4 and 5 were successfully synthesized from the carbocyclic amines 14a or 14b and the imidazole nucleoside 6, as shown in SCHEME 3.
The N-1-substituted adenosine derivatives 15a and 15b were obtained in high yield by the treatment of a mixture of 6 and either amine 14a or amine 14b with K 2 CO 3 in MeOH at room temperature. The 5"-hydroxy group of 15a or 15b was protected with a dimethoxytrityl (DMTr) group, and the 5'-O-TBS group of the product was subsequently removed with TBAF to give 16a or 16b. Treatment of 16a or 16b under the conditions reported by Hata and co-workers with an S,S'-diphenylphosphorodithioate (PSS)/2,4,6-triisopropylbenzenesulfonyl chloride (TPSCl)/pyridine system 8 gave the 5'-bis(phenylthio)phosphate 17a or 17b, respectively. The 5"-O-DMTr group of 17a or 17b was removed to give 18a or 18b, respectively. A phosphoryl group was introduced at the resulting 5"-primary hydroxyl of 18a or 18b by Yoshikawa's method with POCl 3 /(EtO) 3 PO, 9 followed by treatment of the product with H 3 PO 2 and Et 3 N 10 in the presence of N-methylmaleimide (NMM) 5c in pyridine, to afford the corresponding 5'-phenylthiophosphate 19a or 19b, respectively, which was the substrate of the key intramolecular condensation reaction. When a solution of 19a in pyridine was added slowly to a mixture of a large excess of AgNO 3 and Et 3 N in the presence of MS 3A in pyridine at room temperature, 5b,c the intramolecular pyrophosphate linkage was successfully formed as the previously reported cases to give the desired cyclization product 20a in 46% yield. The other substrate 19b was similarly condensed and the cyclization product 19b was obtained. Finally, the protecting groups of 19a and 19b were simultaneously remove by acidic treatment with aqueous HCO 2 H furnished the target cADPcX (4) and 3"-OMe-cADPcX (5).
Ca 2+ -mobilizing Activity in Sea Urchin Egg Homogenate. The Ca 2+ -mobilizing ability of the newly synthesized compounds 4 and 5 was evaluated by the fluorometrically Ca 2+ -monitoring method with H. pulcherrimus sea urchin egg homogenate, 6b,11 and the results were compared those of the natural second messenger cADPR (1) and the related carbocyclic analogues cADPcR (2) and 3"-deoxy-cADPcR (3). Both of the two newly synthesized compounds 4 and 5 released Ca 2+ from the homogenate in a dose-dependent manner, as shown in FIGURE 2, where the maximal Ca 2+ -mobilizing activity was almost equal to that of cADPR. Thus, 4 and 5 were shown to be full agonists as cADPcR (2) and 3"-deoxy-cADPcR (3). cADPcX (4), the 3"-epimer of cADPcR, showed marked Ca 2+ -mobilizing activity with an EC 50 value of 69 nM, which was similar to that of cADPcR with an EC 50 value of 79 nM and was 3 times more potent than the natural ligand cADPR (EC 50 = 220 nM). The 3"-O-methyl cADPcX (5) showed an EC 50 value of 740 nM, which was about 10 times weaker than cADPcX. Similar to the case of cADPcR, 3"-methylation of the 3"-hydroxy group of cADPcX markedly reduced the activity.
CONCLUSION
We successfully synthesized cADPcX (4), the 3"-epimer of cADPcR (2), and the corresponding 3"-O-methyl analogue (3"-OMe-cADPcX, 5) and identified cADPcX as one of the most potent cADPR-related compounds reported so far. Therefore, irrespective of the 3"-configuration, both cADPcX and cADPcR have strong Ca 2+ -mobilizing activity to suggest that the 3"-hydroxy group seems to be unnecessary in their binding with the target biomolecule, which is in accord with the previous results on the 3"-deoxy-cADPcR with remarkable activity. 6c {(1R,2S,3S,4R) N-1-[(1R,2S,3S,4R)-2,3-Bis(methoxymethyloxy)-4-( N-1-[(1R,2S,3S,4R) N-1-[(1R,2S,3S,4R) N-1-[(1R,2S,3S,4R)-2,3-Bis(methoxymethyloxy)-4-(phosphonoxymethyl) 
-2,3-Bis(methoxymethyloxy)-4-(hydroxymethyl)cyclopentyl

]-5'-O-[bis(phenylthio)phospholyl]-2',3'-O-isopropylideneadenosine (18a).
N-1-[(1R,2S,3S,4R)-2-(Methoxymethyloxy)-3-methoxy-4-(hydroxymethyl)cycl opentyl]-5'-O-(tert-butyldimethylsilyl)-2',3'-O-isopropylideneadenosine (15b).
Compound 15b (0.565 g, 84%) was obtained from 6 (0.480 g, 1.10 mmol) and 14b (0.227 g, 1.11 mmol) as described for the synthesis of 15a: 1 N-1-[(1R,2S,3S,4R) 
N-1-[(1R,2S,3S,4R)-2-(Methoxymethyloxy)-3-methoxy-4-(dimethoxytrityloxy
N-1-[(1R,2S,3S,4R)-2-(Methoxymethyloxy)-3-methoxy-4-(hydroxymethyl)cycl opentyl]-5'-O-{bis(phenylthio)phospholyl}-2',3'-O-isopropylideneadenosine (18b).
Compound 18b (0.312 g, 88%) was obtained from 17b (0.496 g, 0.467 mmol) as described for the synthesis of 18a: 1 N-1-[(1R,2S,3S,4R)-2-(Methoxymethyloxy)-3-methoxy-4-( 
SCHEME 2
Reagents and conditions: a) TIPSCl, imidazole, DMAP, DMF, rt, 91%; b) ClCH 2 CO 2 H, DIAD, Ph 3 P, toluene, 0 °C, 74%; c) NaOMe, MeOH, rt, 88%; d) 1) MOMCl, i-Pr 2 NEt, CH 2 Cl 2 , rt, 2) TBAF, THF, rt, 97% (13a) ; e) 1) MeOTf, DTBMP, CH 2 Cl 2 , rt, 2) TBAF, THF, rt, 45% (13b); f) H 2 O, reflux, quant (14a, 14b). 
